Have a feature idea you'd love to see implemented?
Let us know!
IRWD Ironwood Pharmaceuticals Inc
Price (delayed)
$3.98
Market cap
$635.76M
P/E Ratio
66.33
Dividend/share
N/A
EPS
$0.06
Enterprise value
$1.17B
Ironwood Pharmaceuticals is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. The company discovered, developed and are commercializing linaclotide, the
Highlights
The EPS has surged by 101% year-on-year and by 101% since the previous quarter
The net income has soared by 101% YoY and by 101% from the previous quarter
IRWD's revenue is down by 6% YoY and by 3.1% QoQ
Ironwood Pharmaceuticals's gross profit has decreased by 6% YoY and by 3.1% QoQ
Key stats
What are the main financial stats of IRWD
Market
Valuations
Earnings
Shares outstanding
159.74M
Market cap
$635.76M
Enterprise value
$1.17B
Price to earnings (P/E)
66.33
Price to book (P/B)
N/A
Price to sales (P/S)
1.58
EV/EBIT
9.66
EV/EBITDA
9.5
EV/Sales
2.92
Revenue
$400.57M
EBIT
$121.12M
EBITDA
$123.16M
Free cash flow
$146.36M
Per share
Balance sheet
Liquidity
EPS
$0.06
Free cash flow per share
$0.92
Book value per share
-$2.02
Revenue per share
$2.52
TBVPS
$2.47
Total assets
$395.62M
Total liabilities
$717.35M
Debt
$640.26M
Equity
-$321.73M
Working capital
$132.67M
Debt to equity
-1.99
Current ratio
3.92
Quick ratio
3.6
Net debt/EBITDA
4.34
Margins
Efficiency
Dividend
EBITDA margin
30.7%
Gross margin
100%
Net margin
2.3%
Operating margin
28.4%
Return on assets
2%
Return on equity
N/A
Return on invested capital
14.6%
Return on capital employed
34.6%
Return on sales
30.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IRWD stock price
How has the Ironwood Pharmaceuticals stock price performed over time
Intraday
0%
1 week
-10.36%
1 month
-1%
1 year
-56.83%
YTD
-65.21%
QTD
-3.4%
Financial performance
How have Ironwood Pharmaceuticals's revenue and profit performed over time
Revenue
$400.57M
Gross profit
$400.57M
Operating income
$113.61M
Net income
$9.21M
Gross margin
100%
Net margin
2.3%
IRWD's operating margin has surged by 114% year-on-year and by 112% since the previous quarter
The operating income has soared by 113% YoY and by 111% from the previous quarter
IRWD's net margin has surged by 101% year-on-year and by 101% since the previous quarter
The net income has soared by 101% YoY and by 101% from the previous quarter
Growth
What is Ironwood Pharmaceuticals's growth rate over time
Valuation
What is Ironwood Pharmaceuticals stock price valuation
P/E
66.33
P/B
N/A
P/S
1.58
EV/EBIT
9.66
EV/EBITDA
9.5
EV/Sales
2.92
The EPS has surged by 101% year-on-year and by 101% since the previous quarter
The company's equity rose by 7% YoY and by 2.7% QoQ
IRWD's P/S is 61% below its 5-year quarterly average of 4.1 and 54% below its last 4 quarters average of 3.4
IRWD's revenue is down by 6% YoY and by 3.1% QoQ
Efficiency
How efficient is Ironwood Pharmaceuticals business performance
Ironwood Pharmaceuticals's ROIC has soared by 115% YoY and by 113% from the previous quarter
The return on sales has surged by 115% year-on-year and by 113% since the previous quarter
Ironwood Pharmaceuticals's return on assets has surged by 102% YoY and by 101% QoQ
Dividends
What is IRWD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IRWD.
Financial health
How did Ironwood Pharmaceuticals financials performed over time
The total assets is 45% less than the total liabilities
The total assets has contracted by 34% YoY and by 10% from the previous quarter
IRWD's total liabilities is down by 24% year-on-year and by 7% since the previous quarter
IRWD's debt is down by 22% year-on-year and by 7% since the previous quarter
The company's debt to equity rose by 16% YoY and by 4.8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.